Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.33 |
| ▸ | ARG1 | P05089 | 1/20 | 0.32 |
| ▸ | ARG2 | P78540 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14915714 | 1.00 | DGAT1 (0.37) | DGAT1CYP1A2CYP2D6KCNN4ARG1 | |
| SCHEMBL9116850 | 0.80 | DGAT1 (0.40) | DGAT1CYP1A2CYP2D6ARG1ARG2 | |
| SCHEMBL28195825 | 0.80 | DGAT1 (0.40) | DGAT1CYP1A2CYP2D6ARG1ARG2 | |
| SCHEMBL4939145 | 0.80 | DGAT1 (0.40) | DGAT1CYP1A2CYP2D6ARG1ARG2 | |
| SCHEMBL7613000 | 0.80 | CYP1A2 (0.43) | CYP1A2CYP2D6ARG1ARG2 | |
| SCHEMBL27881348 | 0.79 | TAS1R3 (0.32) | — | |
| SCHEMBL2141980 | 0.78 | DGAT1 (0.54) | DGAT1CYP2D6 | |
| SCHEMBL23277645 | 0.76 | KCNN4 (0.35) | DGAT1KCNN4 | |
| Benzene SCHEMBL28806032 | 0.74 | KCNN4 (0.33) | CYP1A2CYP2D6KCNN4SRC | |
| SCHEMBL27923291 | 0.74 | DGAT1 (0.31) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2773634-B1 | ROD-LIKE HEPATITIS C VIRUS INHIBITORS CONTAINING THE FRAGEMENT {2-[4-(BIPHENYL-4-YL)-1H-IMIDAZO-2-YL]PYRROLIDINE-1-CARBONLYMETHYL}AMINE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2018-06-06 | — | — | EP | disclosed |
| US-9669027-B2 | Hepatitis C virus inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-20160038483-A1 | HEPATITIS C VIRUS INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-02-11 | — | — | US | disclosed |
| US-9212168-B2 | Hepatitis C virus inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-12-15 | — | — | US | disclosed |
| CN-103946220-A | Inhibitors of baculovirus containing fragment {2- [4- (biphenyl-4-yl) -1H-imidazol-2-yl ] pyrrolidine-1-carbonylmethyl } amine | THERAVANCE INC | 2014-07-23 | — | — | CN | disclosed |
| US-20130115194-A1 | HEPATITIS C VIRUS INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130115194-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, HDGF | DGAT1 1685/4885CYP1A2 275/4885CYP2D6 446/4885 |
| US-20160038483-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, HDGF | DGAT1 1685/4885CYP1A2 275/4885CYP2D6 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.